Despite recent advancement in therapies, the prognosis of NSCLC patients remains unsatisfactory with a five‐ or 10‐year survival rate of 15%–20% of the total population without EGFR gene mutation or ALK translocation.7 This evidence concerns the gene EGFR and non-small cell lung carcinoma.